Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $87.6 million.

  • Puma Biotechnology's Total Liabilities fell 4146.08% to $87.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.6 million, marking a year-over-year decrease of 4146.08%. This contributed to the annual value of $121.2 million for FY2024, which is 3155.42% down from last year.
  • Per Puma Biotechnology's latest filing, its Total Liabilities stood at $87.6 million for Q3 2025, which was down 4146.08% from $90.2 million recorded in Q2 2025.
  • Puma Biotechnology's 5-year Total Liabilities high stood at $242.2 million for Q1 2021, and its period low was $87.6 million during Q3 2025.
  • Moreover, its 5-year median value for Total Liabilities was $170.4 million (2023), whereas its average is $170.2 million.
  • In the last 5 years, Puma Biotechnology's Total Liabilities skyrocketed by 1206.1% in 2021 and then crashed by 4236.29% in 2025.
  • Puma Biotechnology's Total Liabilities (Quarter) stood at $229.0 million in 2021, then decreased by 12.48% to $200.5 million in 2022, then dropped by 11.66% to $177.1 million in 2023, then plummeted by 31.55% to $121.2 million in 2024, then fell by 27.73% to $87.6 million in 2025.
  • Its last three reported values are $87.6 million in Q3 2025, $90.2 million for Q2 2025, and $99.1 million during Q1 2025.